Cisapride
Propulsid (cisapride) is a small molecule pharmaceutical. Cisapride was first approved as Propulsid on 1993-07-29. It is used to treat constipation, dyspepsia, gastroesophageal reflux, and gastroparesis in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 4. In addition, it is known to target 5-hydroxytryptamine receptor 7 and voltage-gated inwardly rectifying potassium channel KCNH2; potassium voltage-gated channel subfamily H member 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cisapride monohydrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PROPULSID QUICKSOLV | Johnson & Johnson | N-020767 DISCN | 1997-11-07 | 1 products |
| PROPULSID | Johnson & Johnson | N-020398 DISCN | 1995-09-15 | 1 products |
| PROPULSID | Johnson & Johnson | N-020210 DISCN | 1993-07-29 | 2 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
No data
Drug
General
| Drug common name | Cisapride |
| INN | cisapride |
| Description | 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxybenzamide is a member of benzamides. |
| Classification | Small molecule |
| Drug class | sulpride derivatives and analogs |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC |
Identifiers
| PDB | — |
| CAS-ID | 81098-60-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1729 |
| ChEBI ID | — |
| PubChem CID | 2769 |
| DrugBank | DB00604 |
| UNII ID | UVL329170W (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KCNH2
KCNH2
Organism
Homo sapiens
Gene name
KCNH2
Gene synonyms
ERG, ERG1, HERG
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily H member 2
Protein synonyms
Eag homolog, Eag-related protein 1, ERG-1, Ether-a-go-go-related gene potassium channel 1, ether-a-go-go-related potassium channel protein, Ether-a-go-go-related protein 1, H-ERG, hERG-1, hERG1, human ether-a-go-go-related, long QT syndrome type 2, potassium channel, voltage gated eag related subfamily H, member 2, potassium voltage-gated channel, subfamily H (eag-related), member 2, Voltage-gated potassium channel subunit Kv11.1
Uniprot ID
Mouse ortholog
Kcnh2 (16511)
potassium voltage-gated channel subfamily H member 2 (O35989)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Cisapride
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use